Patents by Inventor Darren J. Baker

Darren J. Baker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treating cardiovascular disease by selectively eliminating senescent cells
    Patent number: 11963957
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: December 7, 2020
    Date of Patent: April 23, 2024
    Assignees: Mayo Foundation for Medical Education and Research, Unity Biotechnology, Inc., Buck Institute for Research on Aging
    Inventors: Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Jan M. A. van Deursen, Darren J. Baker, Bennett G. Childs
  • Treating cognitive decline and other neurodegenerative conditions by selectively removing senescent cells from neurological tissue
    Patent number: 11351167
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: June 7, 2022
    Assignees: Buck Institute for Research on Aging, Mayo Foundation for Medical Education and Research, Unity Biotechnology, Inc.
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Darren J. Baker, Jan M. A. van Deursen
  • TREATING CARDIOVASCULAR DISEASE BY SELECTIVELY ELIMINATING SENESCENT CELLS
    Publication number: 20210169875
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Application
    Filed: December 7, 2020
    Publication date: June 10, 2021
    Inventors: Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Jan M.A. van Deursen, Darren J. Baker, Bennett G. Childs
  • TREATING COGNITIVE DECLINE AND OTHER NEURODEGENERATIVE CONDITIONS BY SELECTIVELY REMOVING SENESCENT CELLS FROM NEUROLOGICAL TISSUE
    Publication number: 20210030752
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Application
    Filed: October 8, 2020
    Publication date: February 4, 2021
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Darren J. Baker, Jan M.A. van Deursen, Albert Davalos
  • TREATING COGNITIVE DECLINE AND OTHER NEURODEGENERATIVE CONDITIONS BY SELECTIVELY REMOVING SENESCENT CELLS FROM NEUROLOGICAL TISSUE
    Publication number: 20200030323
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Application
    Filed: September 26, 2019
    Publication date: January 30, 2020
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Darren J. Baker, Jan M.A. van Deursen
  • Removing senescent cells from a mixed cell population or tissue using a phosphoinositide 3-kinase (PI3K) inhibitor
    Patent number: 10517866
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: December 31, 2019
    Assignees: Unity Biotechnology, Inc., Buck Institute for Research on Aging, Mayo Foundation for Medical Education and Research
    Inventors: Remi-Martin Laberge, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Nathaniel David, Alain Philippe Vasserot, Darren J. Baker, Bennett G. Childs, Jan M. A. van Deursen
  • Compositions of matter for treatment of ophthalmic conditions by selectively removing senescent cells from the eye
    Patent number: 10478432
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: November 19, 2019
    Assignees: Unity Biotechnology, Inc., Buck Institute for Research on Aging, Mayo Foundation for Medical Education and Research
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Darren J. Baker, Bennett G. Childs, Jan M. A. van Deursen
  • Unit dose of an aryl sulfonamide that is effective for treating eye disease and averting potential vision loss
    Patent number: 10478433
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: November 19, 2019
    Assignees: Unity Biotechnology, Inc., Buck Institute for Research on Aging, Mayo Foundation for Medical Education and Research
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Darren J. Baker, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Jan M. A. van Deursen, Alain Philippe Vasserot, Bennett G. Childs
  • Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders using an inhibitor of Akt kinase
    Patent number: 10413542
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: September 17, 2019
    Assignees: Buck Institute for Research on Aging, Unity Biotechnology, Inc., Mayo Foundation for Medical Education and Research
    Inventors: Remi-Martin Laberge, Nathaniel David, Alain Philippe Vasserot, Darren J. Baker, Bennett G. Childs, James L. Kirkland, Tamar Tchkonia, Jan M. A. van Deursen, Yi Zhu
  • Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
    Patent number: 10328058
    Abstract: Foamy macrophages with senescence markers accumulate in the subendothelial space at the onset of atherosclerosis where they drive pathology by increasing expression of key atherogenic and inflammatory cytokines and chemokines. In advanced lesions, senescent cells promote features of plaque instability, including elastic fiber degradation and fibrous cap thinning, by heightening metalloprotease production. This invention provides methods and materials for treating arthritis by removing senescent cells in or around atherosclerotic plaques, thereby stabilizing the plaques, inhibiting rupture of the plaques and pathological sequelae that manifest as coronary artery disease.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: June 25, 2019
    Assignees: Mayo Foundation for Medical Education and Research, Unity Biotechnology, Inc., Buck Institute for Research on Aging
    Inventors: Darren J. Baker, Marco Demaria, Albert Davalos, Bennett G. Childs, Jan M. A. van Deursen, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Nathaniel David, Remi-Martin Laberge, Judith Campisi
  • Use of sulfonamide inhibitors of BCL-2 and BCL-xL to treat ophthalmic disease by selectively removing senescent cells
    Patent number: 10328073
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: June 25, 2019
    Assignees: Unity Biotechnology, Inc., Buck Institute for Research on Aging, Mayo Foundation for Medical Education and Research
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Darren J. Baker, Bennett G. Childs, Jan M. A. van Deursen
  • Treating pulmonary conditions by selectively removing senescent cells from the lung using an intermittent dosing regimen
    Patent number: 10258618
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: April 16, 2019
    Assignees: UNITY BIOTECHNOLOGY, INC., BUCK INSTITUTE FOR RESEARCH AGING, MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Darren J. Baker, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Jan M. A. van Deursen
  • Increasing healthy lifespan and delaying progression of age-related phenotypes by selectively removing senescent cells
    Patent number: 10251376
    Abstract: This document relates to methods and materials involved in the removal of senescent cells within a mammal. For example, transgenic non-human animals that can be induced to delete senescent cells are provided.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: April 9, 2019
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: James L. Kirkland, Tamar Tchkonia, Jan M. A. van Deursen, Darren J. Baker
  • PROTOCOL FOR INCREASING LIFE EXPECTANCY IN A TEST SUBJECT
    Publication number: 20190022225
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders. Also included herein are methods for extending lifespan.
    Type: Application
    Filed: June 13, 2018
    Publication date: January 24, 2019
    Inventors: Darren J. Baker, Bennett G. Childs, James L. Kirkland, Tamar Tchkonia, Jan M.A. van Deursen
  • USE OF SULFONAMIDE INHIBITORS OF BCL-2 AND BCL-XL TO TREAT OPHTHALMIC DISEASE BY SELECTIVELY REMOVING SENESCENT CELLS
    Publication number: 20190022090
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Application
    Filed: August 3, 2018
    Publication date: January 24, 2019
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Darren J. Baker, Bennett G. Childs, Jan M.A. van Deursen
  • Pharmaceutical Products and Drug Combinations for Treating Atherosclerosis by Stabilizing Atherosclerotic Plaques and Promoting Plaque Regression
    Publication number: 20190000846
    Abstract: Foamy macrophages with senescence markers accumulate in the subendothelial space at the onset of atherosclerosis where they drive pathology by increasing expression of key atherogenic and inflammatory cytokines and chemokines. This invention provides senolytic agents that remove senescent cells that are present in or around atherosclerotic plaques. The agents inhibit or reverse thinning of the fibrous cap on atherosclerotic plaques. This has the effect of stabilizing the plaques, inhibiting rupture and preventing pathological sequelae that manifest as coronary artery disease. Senolytic agents used in this way complement the action of statins and other drugs that cause plaque regression. Thus, senolytic agents and lipid lowering drugs can be used in combination for enhanced therapeutic effect.
    Type: Application
    Filed: July 2, 2018
    Publication date: January 3, 2019
    Inventors: Jan M.A. van Deursen, Bennett G. Childs, Darren J. Baker, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Nathaniel David, Remi-Martin Laberge, Judith Campisi, Marco Demaria
  • Unit Dose of an MDM2 Inhibitor that Provides Long-Lasting Relief from Idiopathic Pulmonary Fibrosis and other Pulmonary Conditions by Selectively Removing Senescent Cells from the Lung
    Publication number: 20180303828
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Application
    Filed: June 13, 2018
    Publication date: October 25, 2018
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Darren J. Baker, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Jan M.A. van Deursen
  • Nucleic Acid Construct Comprising a P16 Promoter Controlling Expression of a Transgene that Causes Apoptosis in Senescent Cells
    Publication number: 20180279590
    Abstract: This document relates to methods and materials involved in the removal of senescent cells within a mammal. For example, transgenic non-human animals that can be induced to delete senescent cells are provided.
    Type: Application
    Filed: June 14, 2018
    Publication date: October 4, 2018
    Inventors: James L. Kirkland, Tamar Tchkonia, Jan M.A. van Deursen, Darren J. Baker
  • Methods and Compositions for Killing Senescent Cells and for Treating Senescence-Associated Diseases and Disorders
    Publication number: 20180256568
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Application
    Filed: April 11, 2018
    Publication date: September 13, 2018
    Inventors: Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, Darren J. Baker, Bennett G. Childs, James L. Kirkland, Tamar Tchkonia, Jan M.A. van Deursen, Jennifer Elisseeff, Chaekyu Kim, Okhee Jeon, Allyson K. Palmer, Yi Zhu
  • REMOVING SENESCENT CELLS FROM A MIXED CELL POPULATION OR TISSUE USING A PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITOR
    Publication number: 20180250296
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Application
    Filed: May 16, 2018
    Publication date: September 6, 2018
    Inventors: Remi-Martin Laberge, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Nathaniel David, Alain Philippe Vasserot, Darren J. Baker, Bennett G. Childs, Jan M.A. van Deursen